D3L-002 / D3 Bio - LARVOL DELTA

Study of D3L-002 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: D3 Bio (Wuxi) Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Monotherapy • Oncology • Solid Tumor

Study of D3L-002 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: D3 Bio (Wuxi) Co., Ltd

First-in-human • Monotherapy • New P1 trial • Oncology • Solid Tumor

Preclinical characterization of D3L-002, a novel cancer immunotherapy bispecific antibody that elicits potent anti-tumor efficacy via co-blocking TIGIT and PVRIG (SITC 2023) - "In addition, the combination of D3L-002 with anti-PDL1 mAb showed more potent efficacy than Atezolizumab monotherapy (P< 0. Conclusions D3L-002 is a novel TIGIT×PVRIG bsAb which demonstrated potent anti-tumor effect via TIGIT and PVRIG co-blocking in both in vitro and in vivo models. D3L-002 might provide a novel treatment approach for solid tumors and overcome resistance to current ICB therapies."

Preclinical • Oncology • Solid Tumor • CD8 • IFNG • TIGIT

Combination of D3L-002, an anti-TIGIT/PVRIG bispecific antibody, with D3S-001, a KRAS G12C inhibitor, transformed tumor microenvironment from "cold" to "hot" and achieved durable tumor remission in preclinical models. (AACR-NCI-EORTC 2023) - No abstract available

Preclinical • Tumor microenvironment • Oncology • KRAS • TIGIT